Abbott Stock Still Sits Below Fair Value-But Is the 10% Bounce Already Pricing In the Good News?

Even after the 10.71% one-day rebound, Abbott still trades below the fair-value anchor of $116.54, implying it remains 15.2% undervalued on the core estimate. The cash-flow model shows an even larger gap, at 39.5% below intrinsic value. In other words, the bounce changed the timing, not the basic valuation case.

Part of this week's move was psychological. Abbott raised its 2026 adjusted EPS guide to $5.45 to $5.60, helping reverse some of the panic that had weighed on the shares. The stock is still down 20.42% year to date and 16.09% over the past year, so the market may still be pricing downside risk more heavily than current results justify.

Q2 results gave investors operating proof, not just a sentiment shift

In the latest quarter, Abbott delivered 13.0 percent reported sales growth, 4.8% comparable sales growth, and $1.31 adjusted diluted EPS. Management also raised full-year 2026 adjusted diluted EPS guidance to $5.45 to $5.60 while reaffirming 6.5% to 7.5% comparable sales growth. In the same quarter, Abbott returned $2.1 billion to shareholders.

That mix matters. A one-product rally can produce a short-lived bounce, but a broader healthcare platform with growing earnings guidance and meaningful capital return is easier for investors to underwrite over a longer horizon.

Diversity across franchises weakens the "broken business" label

Abbott's recent results also included solid contributions from Medical Devices, reinforcing the idea that the company's appeal is not tied to a single segment. That breadth does not remove risk, but it does make the rerating case more durable than a simple mood swing.

The stock still looks discounted, but positioning matters more now

After the rebound, the better question is no longer whether Abbott looks cheap on paper. It does: still roughly 15.2% below the core fair-value estimate and about 39.5% below the DCF estimate. The harder question is how to act once part of the relief move has already been absorbed.

What would support follow-through

• Consistent execution against the new 2026 adjusted EPS path.
• Sustained top-line momentum, including the company's 6.5% to 7.5% comparable sales growth guidance for the full year.
• Continued capital return after $2.1 billion returned to shareholders in the second quarter.

What could break the bargain case

The cautious view is still credible. Litigation in the nutrition business and pricing pressure in glucose monitoring remain key risks, and either one could limit rerating potential if conditions worsen. For now, the setup still looks closer to a buy-on-confirmation or selective dip scenario than a chase-the-bounce trade.